Welcome to the CAMZYOS® REMS(Risk Evaluation and Mitigation Strategy)

Healthcare Providers: Log into the REMS portal to complete certification in the program. Once certified, use the portal to manage REMS tasks and patients, and to enroll a REMS designee.

Healthcare Provider Login

Pharmacies: The Pharmacy Authorized Representative may log into the REMS portal to complete certification. Once certified, use the portal to invite authorized staff members to manage REMS tasks and patients.

Pharmacy Login

NOTE: This portal cannot be opened in Internet Explorer (IE) or the legacy version of Microsoft Edge available before 2020. The portal can be opened in the version of Microsoft Edge available in January 2020. You can also copy and paste the link into a different browser.

Healthcare Providers

Healthcare providers must be certified in the CAMZYOS REMS in order to prescribe CAMZYOS.

Learn About Healthcare Provider Certification

Patients

Patients must be enrolled
in the CAMZYOS REMS in
order to receive CAMZYOS.

Learn About
Patient Enrollment

Pharmacies

Pharmacies must be certified
in the CAMZYOS REMS in
order to dispense CAMZYOS.

Learn About
Pharmacy Certification

A REMS is a strategy to manage known or potential serious risks associated with a drug. It is required by the US Food and Drug Administration (FDA) to ensure that the benefits of a drug outweigh its risks. Due to the risk of heart failure due to systolic dysfunction, CAMZYOS is only available through a restricted program called the CAMZYOS REMS.

The objectives of the CAMZYOS REMS are to:

  • Monitor for detection of heart failure due to systolic dysfunction with periodic echocardiograms
  • Screen for drug interactions prior to each dispense

INDICATION

CAMZYOS is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.

Please see full Prescribing Information.

Back to top

Healthcare providers must report adverse events of heart failure due to systolic dysfunction associated with CAMZYOS at 833-628-7367.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.